Summary Differentiation inhibitory factor (nm23 protein) inhibited the induction of the differentiation of various leukaemic cell lines. We previously reported that nm23 genes (Hi and H2) were overexpressed in acute myelogenous leukaemia (AML) and nm23-H1 expression predicted the prognosis of AML, especially AML-M5. To clarify the correlation between French-American-British (FAB) classification and nm23 expression level and to clarify the involvement of nm23-H2 and nm23-H1 in patient survival, we investigated the relative levels of nm23-Hi and -H2 mRNA in 76 AML samples using the reverse transcriptase-polymerase chain reaction. We confirmed that the expression of both nm23-Hl and -H2 genes in AML samples from three different hospitals was significantly higher than that in normal blood cells (P < 0.0005). Overexpression of nm23-H1 was observed in each FAB AML-M1, -M2, -M3, -M4 or -M5 subtype, and the predictive effect of nm23-Hl expression on AML prognosis was shown in FAB AML-M2 and -M5 cases. Although overexpression of nm23-H2 was also found in each FAB subtype, the expression of nm23-H2 in AML-M1 and -M3 cells was not significantly higher than that in normal cells. Among AML subtypes, AML-M3 showed the lowest expression levels of both nm23 genes. To understand the relationship between nm23-H1 and -H2 expression levels, nm23 expression levels for all the AML cases were plotted and divided into four groups (group A, nm23-H1 and -H2 both high; B, both low; C, only nm23-Hl high; D, only nm23-H2 high). A statistically significant correlation between the levels of expression of nm23-Hl and -H2 was observed (r= 0.726). Most AML-M3 cases belonged to group B, but not other types of AML. Analysis of survival probability between the groups showed that group B survived for significantly longer compared with group A. Furthermore, AML-M3 cases survived for significantly longer compared with non-M3 cases in the same group B. These data suggest that low expression levels of both nm23-Hl and -H2 are associated with good prognosis in AML patients.
The degree of differentiation is an important prognostic factor in leukaemia. For example, patients with leukaemia of the undifferentiated phenotype have a lower response rate to treatment and poor survival. Induction of differentiation is closely linked to loss of leukaemogenicity and blocks expression of the malignant phenotypes. Conversely, a disorder of the cellular differentiation of malignant cells reflects clinical behaviour and therapeutic responses. Normal haematopoiesis can be controlled by various positive and negative regulatory molecules. In myeloid leukaemia, these signals continue to operate, but in an unbalanced fashion, allowing emergence and eventual dominance of a malignant clone. Leukaemic cells are arrested in less differentiated stages of development. These results suggest that negative regulators are also important to regulate differentiation of leukaemic cells in addition to positive regulators. We previously reported that a non-differentiating mouse myeloid leukaemia cell line produced differentiation inhibiting factors. Suppression of the production of the inhibitory factors resulted in the non-differentiating leukaemic cells becoming sensitive to differentiation inducers. One of the factors was purified as a homologue of nm23 (Okabe-Kado et al, 1992) .
Nm23 proteins are involved in tumour metastasis regulation and have nucleoside diphosphate (NDP) kinase enzyme activity (Steeg et al, 1988; De La Rosa et al, 1995) . There are two types of human nm23 gene, namely nm23-HJ and nm23-H2. The proteins encoded by nm23-H] and -H2 show 88% amino acid sequence homology and the genes locate on the same region of chromosome 17q21 in tandem (Gilles et al, 1991; Stahl et al, 1991; Backer et al, 1993; Chandrasekharappa et al, 1993; Okada et al, 1994) . We found that a differentiation inhibitory factor (I-factor) purified from a differentiation-resistant mouse myeloid leukaemia cell line was identical to the nm23 protein (Okabe-Kado et al, 1992) . The nm23-Hl and -H2 proteins inhibited the induction of the differentiation of mouse myelogenous leukaemia M1 and WEHI-3BD+ and human erythroleukaemia HEL, KU812, and K562 cells. The I-factor activity was independent of NDP kinase activity and required the presence of the N-terminal 60 amino acids (Okabe-Kado et al, 1995a,b) . Based on the biological activity of nm23 proteins for Ifactor, we previously investigated the relative levels of nm23-HI and -H2 transcripts in AML and chronic myelogenous leukaemia (CML) cells. nm23-H] and -H2 were overexpressed in AML but not in CML in the chronic phase, and nm23-HJ expression predicted the prognosis of AML, especially of AML-M5 (Yokoyama et al, 1996) . In this study, we examined additional cases of AML from a different hospital to confirm the clinical implication of nm23-HJ expression on AML by multicentre analysis, analysed the relationship between the expression of both *P < 0.0005; **P < 0.05; ***P < 0.01 (Yokoyama et al, 1996 Quantitative RT-PCR was performed using a GeneAmp RNA PCR kit (TaKaRa, Tokyo, Japan). The oligonucleotides used in PCR amplification were as follows: sense strand, 5'-ATGGCCAACTGTGAGCGTACC-3'; antisense strand, 5'-CATGTATTTCACCAGGCCGGC-3' for nm23-HJ; sense strand, 5'-ATGGCCAACCTGGAGCGCACC-3', antisense strand, 5'-TCCCCACGAATGGTGCCTGGC-3' for nm23-H2; sense strand, 5'-ACATCGCTCAGACACCATGG-3', antisense strand, 5'-GTAGTTGAGGTCATGAAGGG-3' for GAPDH. Based on the sequence information around the intron-exon junctions of each gene, the primers were designed to sandwich one intron and, thus, to specifically detect mRNA. RNA (0.2 ,ug) was reverse transcribed to synthesize cDNA using random nonamers at 42°C, then amplified by means of the PCR using specific primers (4 pmol) and 0.11 Mbq of [cC-32P]dCTP (110 Tbq mmol-') in 20-gl mixtures consisting of 10 mM Tris-HCl (pH 8.3), 50 mm potassium chloride, 1.2 mm magnesium chloride and 0.2 mm dNTPs (dATP, dTTP, dGTP, dCTP). The PCR comprised 35 cycles for nm23-HJ and 25 for nm23-H2 and GAPDH, with denaturing at 95°C for 1 min, annealing at 60°C for 1 min and extension at 72°C for 0.5 min. The reaction was performed in a GeneAmp PCR system 9600 (Perkin Elmer, Norwalk, CT, USA). The PCR products were then subjected to 6% polyacrylamide gel electrophoresis, and the radioactivity level in the dried gel was evaluated by means of autoradiography using a Fuji Bio-Image Analyzer BAS2000 (Fuji Film, Tokyo, Japan). The linearity of the quantitation of RT-PCR products of nm23-HI, nm23-H2 and GAPDH was determined as previously described (Yokoyama et al, 1996) . To normalize the differences in RNA loading for RT-PCR and RNA degradation in individual samples, the values of the nm23-H] and -H2 gene expression were divided by that of the GAPDH gene for comparison with the values in erythroleukaemia HEL cells defined as 100 (the expression index). The mRNA levels and the number of patients are shown in Table 2 . 
Statistical analysis
Statistical comparisons between groups were performed by means of Student's t-test, and values of P < 0.05 were considered significant. Survival curves of patients were prepared using the Kaplan-Meier method, and statistical analysis of the difference between the survival curves was undertaken using the log-rank tests.
RESULTS
We examined nm23-HJ and -H2 mRNA expression levels of an additional 34 AML cases from the National Defence Medical College Hospital, Japan. Expression levels of nm23-HJ and -H2 genes in these AML cases were significantly higher than that in normal blood cells (Student's t-test, P < 0.01). Elevated nm23-HJ mRNA levels were associated with significantly reduced overall survival (log-rank test, P < 0.05). These results using AML samples from another centre confirm our previous findings. We combined the present data with previous data for further analysis of the clinical implication of nm23 mRNA overexpression.
Levels of nm23-H1 and -H2 expression and FAB classification of AML patients Data for 76 AML samples were available and we were able to analyse the relationship between the levels of nm23-HJ and -H2 expression and FAB classification of AML patients, except for AML-MO and -M6. Table 1 shows the levels of nm23-HJ and -H2 mRNA in normal blood cells and AML cells of each FAB subtype. The average levels of nm23-HJ and -H2 expressions in the AML samples were significantly higher than that in normal blood cells (P < 0.0005). The level of nm23-HJ expression was significantly higher in the AML-M 1, -M2, -M3, -M4 and -M5 subtypes than that in normal cells and the level of nm23-H2 expression was significantly higher in AML-M2, -M4 and -M5 than that in normal cells. Although AML-Ml and -M3 cases also had higher expression levels of nm23-H2, they were not statistically significantly higher.
In AML-M6 cases, extremely high expression levels of both nm23 genes were observed, but the statistical significance of this could not be determined because only two cases were investigated. For the same reason, the difference in expression levels between AML-MO patients and normal subjects was not significant.
The clinical backgrounds and nm23-HJ and -H2 expression levels of 76 AML patients are summarized in Table 2 . There was no significant difference in nm23-HJ and -H2 expression levels between groups separated based on gender, age, initial white blood cell count and initial LDH level. Thus, we confirmed that the nm23-HJ and -H2 expression levels in all the AML patients were significantly higher than that in normal subjects, and we observed the overexpression of both nm23 genes in the AML-M2, -M4 and -MS subtype. AML-M1 and -M3 samples also exhibited overexpression of nm23-HJ mRNA, but the increase in nm23-H2 mRNA levels was not statistically significant. Figure 2 Comparison of survival period in two groups of M2 cases. Patients with high nm23-H1 expression levels (> 100) (n = 8) had a worse prognosis than those with low nm23-H1 expression levels (<100) (n = 11) (Student's t-test, P = 0.0026). The survival period of AML-M2 patients with t (8,21) (n = 10) was not statistically different from those without t (8,21) (n = 9) (P= 0.0735) (Figure 1 ). The cut-off value in nm23-HI is 100 and in nm23-H2 it is 120, as reported previously (Yokoyama et al, 1996) . Classification by nm23-H1 and -H2 expression levels and survival of AML patients We previously found that the nm23-HI mRNA level, but not the nm23-H2 mRNA level, was associated with sensitivity to initial chemotherapy and the survival of patients with AML, especially AML-M5 (Yokoyama et al, 1996) . Here we have confirmed that AML-M5 patients (six M5 cases) with low nm23-HI expression levels under 100 exhibited significantly higher rates of survival than those (eight M5 cases) with higher levels over 100 (log-rank test, P < 0.025). We also found that elevated nm23-HJ mRNA levels were associated with significantly reduced survival of AML-M2 patients (high eight M2 cases vs low 11 M2 cases), while the presence of t(8;21) in AML-M2 patients was not associated with the overall survival (Figure 2 and survival probability of patients. As shown in Table 4 , the CR ratios of groups A, B, C and D were 50%, 73%, 57% and 100% respectively. Although the groups with higher expression levels of nm23-HJ (group A + C) showed lower CR ratios than did the other groups, the CR ratio of group A was similar to that of group C. The CR ratios of the groups with higher expression levels of nm23-H2 (group A + D) were similar to those of the other groups. The sensitivity to initial chemotherapy seems to be associated with the nm23-H] expression level rather than the nm23-H2 expression level. Next, we compared the survival probability between the four groups; group A vs B, A vs C, A vs D, B vs C, B vs D and C vs D. Group B exhibited significantly longer survival times compared with group A (log-rank test, P < 0.005, Figure 3A and Table 5 ), although the comparisons between all the other groups indicated no significant difference in survival time (Table 5 ). When we compared the survival probability between the two groups divided by nm23-HJ expression levels (group A+C vs group B+D), group B+D exhibited significantly longer survival times than did group A+C (log-rank test, P < 0.01, Table 5 ). The survival probability between the two groups divided by nm23-H2 expression levels (group A+D vs group B+C) seems to be different, but the difference was not statistically significant (log-rank test, 0.05 < P < 0.10, Table 5 ). These results indicate that lower expression levels of both nm23-H] and -H2 is a better prognostic factor than that of only nm23-Hl, as the P-value obtained by the log-rank test of A vs B is higher than that of A+C vs B+D. As described above, most AML-M3 cases belong to group B, and this group exhibited significantly longer survival times than did group A (log-rank test P < 0.005, Figure 3A) . AML-M3 cases in group B (group B 1) exhibited significantly longer survival times in comparison with non-M3 cases in the same group (group B2, logrank test, P < 0.05). The survival times of group B2 are statistically longer than those of group A (log-rank test, P < 0.05, Figure   3B ), suggesting that lower expression levels of both nm23-HJ and -H2 are associated with good prognosis in AML. In the AML-M3 cases, there may be other factors regulating the abnormal growth and differentiation of the leukaemic cells. DISCUSSION nm23-H] was discovered on the basis of its reduced expression level in highly metastatic murine melanoma cell lines, compared with related, weakly metastatic melanoma cell lines (Steeg et al, 1988) . nm23-H2, a closely related gene, was identified by crosshybridization with nm23-HI on screening of a human fibroblast cDNA library (Stahl et al, 1991) . Reduced nm23-HJ expression levels have been correlated with reduced patient disease-free or overall survival time or other histopathological indicators of high metastatic potential in cohorts of breast, ovarian, cervical, gastric and hepatocellular carcinoma and melanoma. However, the opposite trend has been identified in neuroblastoma, pancreatic carcinoma, lymphoma and leukemia (De La Rosa, 1995) . We previously reported that nm23-HI and nm23-H2 were overexpressed in AML and the higher significance of nm23-HJ expression correlated with a poor prognosis in AML. It has also been reported that among malignant lymphomas, high-grade nonHodgkin's lymphoma (NHL) and Hodgkin's lymphoma samples exhibited significantly higher nm23-HJ expression levels than did low-grade NHL samples. These studies suggest that nm23-H] expression in human haematopoietic malignancies is associated with disease aggressiveness. In this study, we confirmed the clinical implication of nm23-HJ expression for AML on a larger scale than in our previous study and clarified the involvement of nm23-H2 expression levels on the prognosis of AML, as nm23-H2 was also significantly overexpressed in AML (Table 1) , and a statistically significant correlation between the levels of expression of nm23-H] and -H2 was observed in AML ( Figure 1 ). As reported previously for the 42 AML cases, the overall survival of the AML patients with a high (>100) or low (<100) nm23-H2 index was not statistically different (P = 0.6384), even when the cut-off points were varied. In this study of 76 AML cases, the overall survival of the AML patients with a low nm23-H2 index (group B+C) was not significantly higher than those with a high nm23-H2 index (group A+D), although the P-value came close to being significant (0.05 < P < 0.10) ( Table 5 ). Group B (both expression levels low) exhibited significantly longer survival times than did group A (both expression levels high) (log-rank test, P < 0.005, Figure 3A and Table 5 ). These results suggest that the nm23-H2 expression level may be a weak prognostic factor for AML and the combination of nm23-H2 and nm23-H] expression is a better prognostic factor than only nm23-HJ expression alone.
Based on analysis of the promoter regions of nm23-HJ and -H2, it is suggested that both nm23 genes are independently and differentially regulated (Okada et al, 1996) . However, a significant correlation between the levels of expression of nm23-HJ and -H2 was observed in AML ( Figure 1) . Interestingly, group D seemed to have a good response to the first chemotherapy and 50% of group D were AML-M4 cases (Table 4 ). The ratio of nm23-HJ to nm23-H2 expression levels may provide useful information, as the ratio (H l/H2) in total AML was higher than that for normal blood cells and similar to that for the HEL leukaemic cell line, and the ratio in AML-M3 and -M4 cases is close to that of normal cells (Table 1) .
In this study, we also clarified the correlation of nm23 expression levels with FAB classification (Table 1 and Table 3 ). Among AML subtypes, AML-M5 showed relatively higher expression levels than did the other FAB subtypes, although the difference in nm23 expression levels between M5 and non-M5 AML was not statistically significant (Table 3) . On the other hand, we have found that AML-M3 cases have the lowest nm23 expression levels, a lower HI/H2 ratio and better prognosis in comparison with the other FAB subtypes in AML. The low expression of nm23 in AML-M3 may be associated with granulocytic differentiationassociated characteristics and with potential to differentiate into mature cells with all-trans retinoic acid (ATRA). nm23 proteins were purified as differentiation inhibitory factors from nondifferentiating myeloid leukaemia cells (Okabe-Kado et al, 1992). Yamashiro et al (1994) have reported that down-regulation of nm23 gene expression is observed during the induced differentiation of some human leukaemia cell lines. These results suggest that AML-M3 cells are at a certain stage of granulocytic maturation and down-regulation of nm23 gene expression accompanies the maturation. It remains to be determined whether inhibition of nm23 expression affects the induction of the differentiation of leukaemia cells.
AML-M6 (erythroleukaemia) cases had extremely high expression levels of both nm23 genes and the ratio (Hl/H2) was also extremely high, although only two cases were investigated (Table  1) . It would be interesting to clarify whether the erythroid differentiation-associated properties are related to the overexpression of nm23 genes. nm23 as a prognostic factor in AML 2303
Recently the nm23 protein was reported to have a specific interaction with ROR/RZR nuclear receptors (Paravicini et al, 1996) , and the interaction required the presence of the N-terminal 60 amino acids of the nm23 protein predicted to be important for the I-factor activity of nm23 protein (Okabe-Kado et al, 1995) . The receptors for the retinoids are prominent members of the nuclear receptor superfamily and RORIRZR receptors have been identified by homology cloning. They are known as orphan receptors, referring to the fact that their ligands are unknown. RORa is expressed in a variety of organs with the highest levels of specific mRNA detected in leucocytes. It is of interest to examine the expression levels of RORa in leukaemia cells. Although the biological implication of ROR/RZR is unknown, it is tempting to speculate that retinoic acid receptor (RAR) and/or other nuclear receptors might interact with the nm23 protein and participate in the down-regulation of nm23 expression. A good prognosis in AML-M3 is not solely related to nm23 expression, as the survival times of AML-M3 cases were much longer than those of non-M3 AML cases in the same low nm23 expression level group ( Figure  3 ). AML-M3 is associated with a consistent t(l5; 17) translocation that fuses the promyelocytic leukaemia (PML) gene to the RARax gene. Although the PML-RAR fusion protein is a major prognostic factor in AML-M3, the translocation (15;17)(q22;ql2) found in AML-M3 might affect the expression of nm23 genes located on chromosome 17q2 1. We are now examining whether the levels of nm23 expression affect the sensitivity of AML-M3 patients to ATRA treatment and whether they change during the disease progression of AML-M3 patients.
